Tibet Aim Pharm (SZSE:002826) 3-Year EBITDA Growth Rate : 8.30% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Tibet Aim Pharm 3-Year EBITDA Growth Rate?

Tibet Aim Pharm's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.18.

During the past 12 months, Tibet Aim Pharm's average EBITDA Per Share Growth Rate was -10.90% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 8.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Tibet Aim Pharm was 23.50% per year. The lowest was -22.80% per year. And the median was 0.15% per year.

Competitive Comparison of Tibet Aim Pharm's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Aim Pharm's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tibet Aim Pharm's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Aim Pharm's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Tibet Aim Pharm's 3-Year EBITDA Growth Rate falls into.

Tibet Aim Pharm 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Tibet Aim Pharm (SZSE:002826) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Tibet Aim Pharm 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Tibet Aim Pharm's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Tibet Aim Pharm (SZSE:002826) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tibet Aim Pharm Inc (SZSE:002826) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

No. 6, Linqionggang Road, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000

Website

http://www.emyy.cn

Tibet Aim Pharm Inc is the pharmaceutical company based in China. It is mainly engaged in the research and development, production and sales of chemical drugs and proprietary Chinese medicines for common chronic disease such as diabetes and cardiovascular disease as well as medicines for gynecology and obstetrics. The company's products offering includes miglitol tablets, gualoupi injection, nalmefene hydrochloride injection, carbetocin injection; hongjin xiaojie tablets and aceclofenac enteric-coated tablets. The company also expanded its products in the treatment of antibiotic, antiallergic and digestive system.

Executives

Peng Hui	Director
Pang Guo Qiang	Directors, executives
Li Qian Jin	Securities Affairs Representative
Liu Hang	Supervisors

Tibet Aim Pharm (SZSE:002826) Headlines

No Headlines